Prosecution Insights
Last updated: April 19, 2026

Revance Therapeutics Inc.

5 pending office actions

Portfolio Summary

5
Total Pending OAs
4
Final Rejections
1
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18414311 Albumin-Free Botulinum Toxin Formulations OGUNBIYI, OLUWATOSIN A 1645 Non-Final OA Jan 16, 2024
18359633 Methods of Treating or Preventing Migraine or Repetitive Occurrence of Common Migraine Headaches in a Subject Having Underlying Condition(s) DUTT, ADITI 1675 Final Rejection Jul 26, 2023
18031861 METHODS FOR TREATING CERVICAL DYSTONIA MONDESI, ROBERT B 1652 Final Rejection Apr 13, 2023
17912513 INJECTABLE BOTULINUM TOXIN METHODS FOR TREATING HEADACHES SWIFT, CANDICE LEE 1657 Final Rejection Sep 18, 2022
17234690 BOTULINUM TOXIN AND THE TREATMENT OF PRIMARY DISORDERS OF MOOD AND AFFECT DUTT, ADITI 1675 Final Rejection Apr 19, 2021

Managing Revance Therapeutics Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month